[Role of oral hypoglycemic agents in the therapeutic approach to diabetic obesity].
Insulin resistance is the principal physiopathological characteristic of diabetes mellitus type II. Weight loss is the first therapeutic requirement. Oral agents (mainly sulfonylureas) are advisable when the diet alone does not ensure a satisfactory metabolic control. The extrapancreatic action of sulfonylureas induces hypoglycemia through a decrease in peripheral insulin resistance originating in an increase in the number of insulin receptors and in the sensitivity of peripheral tissues to insulin. The pancreatic and extrapancreatic effects, metabolism and indications of sulfonylureas, as well as the problems which arise during their prescription are reviewed. Biguanides belong to a different family of drugs and are less and less prescribed.
D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000503:physiopathology; D004347:Drug Interactions; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D009765:Obesity; D011972:Receptor, Insulin / Q000187:drug effects; D013453:Sulfonylurea Compounds / Q000627:therapeutic use
D007004:Hypoglycemic Agents; D007328:Insulin; D013453:Sulfonylurea Compounds; D011972:Receptor, Insulin
La place des hypoglycémiants oraux dans l'approche thérapeutique de l'obèse diabétique.